Breast cancer treatment sees advancements in genetic testing and targeted therapy

Recent medical advancements offer new pathways for breast cancer management, focusing on personalized diagnostics and targeted therapies.

Results from the OPTIMA study, presented at the American Society of Clinical Oncology (ASCO) annual meeting, indicate that the Prosigna genetic test can help more than half of women with the most common form of early-stage breast cancer avoid chemotherapy without compromising prognosis. The test utilizes the PAM50 signature to analyze the expression of 50 different genes, classifying tumors into molecular subtypes and calculating a Risk of Recurrence (ROR) score.

Additionally, the FDA has approved a new pill combination from Eli Lilly consisting of imlunestrant and abemaciclib. This treatment targets adult patients with locally advanced or metastatic ER-positive, HER2-negative breast cancer that has progressed following hormone therapy due to an ESR1 mutation. The combination works by simultaneously inhibiting estrogen receptors and blocking CDK4/6 proteins to prevent cancer cell growth.